DNA polymerase

CRISPR-Cas9 Knock-In Efficiency Enhanced Using Small-Molecule Inhibitor Pair, Study Shows

Retrieved on: 
Monday, August 21, 2023
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Other Science, Science, Theta, Cas9, NGS, DNA, CRISPR, Nature Communications, DNA polymerase, Biomedical Research, Protein, Promega, AstraZeneca, Vaccine

A new study published in Nature Communications demonstrates how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing.

Key Points: 
  • A new study published in Nature Communications demonstrates how small molecule inhibitors can be used to improve the precision and efficiency of CRISPR-Cas9 gene editing.
  • The results demonstrate how this groundbreaking technique can be enhanced by using two inhibitors to boost insertion rates and reduce off-target effects.
  • Their findings are key to advancing the use of CRISPR techniques in research and clinical applications using a wide range of cell lines.
  • This strategy, dubbed 2iHDR, outperformed previously described strategies that aimed to increase knock-in efficiency with small molecule inhibitors.

IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)

Retrieved on: 
Monday, August 21, 2023
Theta, GSK, DNA, Therapy, Neoplasm, HRD, POLQ, Cancer, Research, MMEJ, DNA polymerase, Investigational New Drug, Patient, Homologous recombination, Medicine, HR, BRCA, FDA, PARP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, DNA repair, Pharmaceutical industry, IND

We are also targeting the Werner Helicase development candidate nomination later this year with GSK, which represents our fifth potential first-in-class program," said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.

Key Points: 
  • We are also targeting the Werner Helicase development candidate nomination later this year with GSK, which represents our fifth potential first-in-class program," said Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences.
  • GSK101 is a potential first-in-class small molecule inhibitor of the helicase domain of DNA Polymerase Theta (Pol Theta).
  • The Pol Theta enzyme facilitates DNA repair through microhomology-mediated end joining (MMEJ), an enzymatic function that enables reversion of BRCA mutations.
  • GSK will lead clinical development for the Pol Theta program pursuant to its global, exclusive license to develop and commercialize the Pol Theta Helicase Inhibitor DC (GSK Pol Theta License).

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Biology, DNA repair, Telomeres, DNA, Non-homologous end joining, DNA polymerase, Poly (ADP-ribose) polymerase, Homologous recombination, BRCA1, DNA polymerase mu, DNA polymerase lambda

These results show that Pol inhibitors exhibited exquisite selectivity and on-target activity, affecting only Pol-Mediated End Joining and not other forms of DNA repair.

Key Points: 
  • These results show that Pol inhibitors exhibited exquisite selectivity and on-target activity, affecting only Pol-Mediated End Joining and not other forms of DNA repair.
  • Dr. Graeme Smith, Chief Scientific Officer of Artios Pharma, said: This preclinical dataset further strengthens the scientific foundation of our Pol inhibitor program.
  • Artios small molecule Pol inhibitors provided nanomolar potent, selective, allosteric inhibition of the polymerase function of DNA polymerase Pol, selectively inhibiting Theta-Mediated End Joining DNA repair without targeting Non-Homologous End Joining or Homologous Recombination.
  • Sensitivity of BRCA1, Shieldin-defective tumours to Pol inhibition was confirmed in vivo laying the foundations for preclinical and clinical development.

Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets

Retrieved on: 
Monday, June 1, 2020
Chemistry, Branches of biology, Biology, Codexis, Biotechnology, DNA replication, DNA polymerase, Enzyme, DNA

The Codexis-developed DNA polymerase has been engineered to deliver high fidelity and uniformity of coverage, providing an accurate and representative DNA diagnostic result.

Key Points: 
  • The Codexis-developed DNA polymerase has been engineered to deliver high fidelity and uniformity of coverage, providing an accurate and representative DNA diagnostic result.
  • This new collaboration will leverage the experience and industry knowledge of the Alphazyme team to accelerate the market introduction of Codexis portfolio of high-performing life science and diagnostic enzymes, while providing Alphazyme exclusive manufacturing and co-marketing rights to certain CodeEvolver-improved enzymes.
  • This partnership will jointly promote and sell these enzymes to innovators in life science and diagnostic markets.
  • In partnership with Alphazyme, Codexis can play a key role in providing solutions to critical molecular biology challenges across a number of applied markets.

DGAP-News: 4basebio AG: Simple and rapid SARS-CoV-2 diagnostic test project with 4basebio's contribution receives funding from 'la Caixa' Banking Foundation

Retrieved on: 
Wednesday, May 20, 2020
Branches of biology, Biology, Molecular biology, DNA replication, Enzymes, Biotechnology, Primase, Polymerase, Polymerase chain reaction, Reverse transcriptase, DNA polymerase, DNA

The project has been selected as one of six to receive funding from 349 high quality applications submitted for funding to the CaixaImpulse Express Call on COVID-19.

Key Points: 
  • The project has been selected as one of six to receive funding from 349 high quality applications submitted for funding to the CaixaImpulse Express Call on COVID-19.
  • This research program, as already announced by 4basebio on 22 April 2020 , is intended to develop a new way of diagnosing SARS-CoV-2 based on Phi29 DNA polymerase amplification.
  • 4basebio will supply the enzymes and technical support within this project.
  • Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.

DGAP-News: 4basebio AG: 4basebio provides Phi29 DNA polymerase variants and expertise to develop improved detection system for SARS-CoV-2 infection

Retrieved on: 
Wednesday, April 22, 2020
Branches of biology, Biology, DNA replication, Enzymes, Molecular biology, Biotechnology, Primase, Severe acute respiratory syndrome-related coronavirus, DNA polymerase, Polymerase, DNA, Reverse transcriptase

Heidelberg, Germany and Cambridge, UK, 22 April 2020 - 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announced today its support to develop a faster and more sensitive test for SARS-CoV-2 infection.

Key Points: 
  • Heidelberg, Germany and Cambridge, UK, 22 April 2020 - 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announced today its support to develop a faster and more sensitive test for SARS-CoV-2 infection.
  • The goal is to pave the way to an industrially scalable test, boosting the capacity of early SARS-CoV-2 detection.
  • Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.
  • The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).